<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03996200</url>
  </required_header>
  <id_info>
    <org_study_id>STAR-III (ISM08)</org_study_id>
    <nct_id>NCT03996200</nct_id>
  </id_info>
  <brief_title>MINIject in Patients With Open Angle Glaucoma Using Single Operator Delivery Tool</brief_title>
  <official_title>A Prospective, Open, Multicentre Clinical Trial Analysing the Efficacy and Safety of Miniject (MINI SO627) in Patients With Open Angle Glaucoma Uncontrolled by Topical Hypotensive Medications Using a Single Operator Delivery Tool</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>iSTAR Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>iSTAR Medical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to assess safety and performance of MINIject SO627 in patients with open angle
      glaucoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will evaluate the efficacy and safety of MINI SO627 and IOP (Intra- ocular
      pressure) lowering effects with or without the use of glaucoma medications. The procedure
      will be a stand alone surgery. Patient follow up with several examinations up to 24 months
      after surgery.

      The primary endpoint is the reduction in medicated mean diurnal IOP at 6 months follow up
      compared to medicated diurnal IOP at baseline visit.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 23, 2019</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Actual">February 14, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>MINIject SO627</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>medicated diurnal IOP</measure>
    <time_frame>6 months post surgery</time_frame>
    <description>Change in medicated diurnal IOP</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Glaucoma, Open-Angle</condition>
  <condition>Glaucoma Eye</condition>
  <arm_group>
    <arm_group_label>MINIject CS627 implant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MINIject 627 implant is used to reduce intra-ocular pressure in the eye. It is implanted through a minimally-invasive glaucoma surgical intervention in a stand alone procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MINIject CS627 implant</intervention_name>
    <description>MINI SO627 is an integrated system comprising a minimally-invasive Glaucoma Drainage Implant (CS627) and a single operator delivery tool.
The delivery tool is a single-use tool, designed for inserting the CS627 implant into the suprachoroidal space in the eye.</description>
    <arm_group_label>MINIject CS627 implant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of primary or secondary open angle glaucoma during screening/baseline visit
             or earlier.

          -  Grade 3 or grade 4 according to Shaffer Angle Grading System.

          -  Glaucoma not adequately controlled by one to four different topical hypotensive
             medication(s), given each for at least one month, as confirmed by 21mmHg &lt; IOP &lt; 35
             mmHg in the study eye at baseline visit.

        Exclusion Criteria:

          -  Grade 2 (narrow, 20 degrees), grade 1 (extremely narrow, less or equal to 10 degrees)
             and grade 0 (closed or slit) according to Shaffer Angle Grading System in the study
             eye.

          -  Neovascular glaucoma in the study eye.

          -  Corneal opacity or iridocorneal angle not visible through gonioprism in the study eye,
             preventing correct placement of the implant in the stud eye.

          -  Prior glaucoma surgery in the study eye.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zubair Hussain</last_name>
    <role>Study Director</role>
    <affiliation>iSTAR</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinica Oftalmologica del Caribe</name>
      <address>
        <city>Barranquilla</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maxivision Eye Hospital</name>
      <address>
        <city>Hyderabad</city>
        <state>Telangana</state>
        <zip>500034</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Panama Eye Center</name>
      <address>
        <city>Panama City</city>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Colombia</country>
    <country>India</country>
    <country>Panama</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>June 21, 2019</study_first_submitted>
  <study_first_submitted_qc>June 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 24, 2019</study_first_posted>
  <last_update_submitted>April 6, 2020</last_update_submitted>
  <last_update_submitted_qc>April 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>glaucoma</keyword>
  <keyword>medical device</keyword>
  <keyword>MIGS</keyword>
  <keyword>drainage device</keyword>
  <keyword>eye</keyword>
  <keyword>reduction IOP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

